CSIMarket
 
Invivo Therapeutics Holdings Corp   (NVIV)
Other Ticker:  
 
 
Price: $0.3207 $-0.17 -34.283%
Day's High: $0.409 Week Perf: -39.03 %
Day's Low: $ 0.30 30 Day Perf: -58.88 %
Volume (M): 1,886 52 Wk High: $ 1.64
Volume (M$): $ 605 52 Wk Avg: $1.05
Open: $0.41 52 Wk Low: $0.22



 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 3
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -9
 Cash Flow (TTM) (Millions $) -2
 Capital Exp. (TTM) (Millions $) 0

Invivo Therapeutics Holdings Corp
Invivo Therapeutics Holdings Corp is a medical technology company based in the United States. The company develops and commercializes treatment options for patients with spinal cord injuries. Invivo Therapeutics focuses on developing innovative biomaterials and biotechnology to help restore patients' neurological function and improve their quality of life. Their flagship product is the Neuro-Spinal Scaffold, an investigational device designed to be surgically implanted at the site of injury to provide structural support and facilitate tissue regeneration. Invivo Therapeutics is committed to advancing the standard of care for spinal cord injury patients and addressing the unmet medical needs in this field.


   Company Address: 1500 District Avenue Burlington 1803 MA
   Company Phone Number: 863-5500   Stock Exchange / Ticker: NASDAQ NVIV
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Invivo Therapeutics Holdings Corp

Revolutionizing the Future: NVIV Unveils Game-Changing Results for Medical Equipment & Supplies Sector Beyond Expectations



Invivo Therapeutics Holdings Corp, a leading Medical Equipment & Supplies company, recently disclosed its financial report for the July to September 2023 reporting cycle. While stockholders did not anticipate significant revenue changes, there were some notable developments that caught their attention, particularly regarding the company's operating loss. With shareholders eagerly awaiting additional revenue sources, there is clear optimism surrounding Invivo's future prospects. Moreover, the company's gradual reduction in losses showcases their determination to establish themselves as a prominent player in the industry. Let's delve deeper into these facts and examine Invivo Therapeutics Holdings Corp's trajectory.
Operating Loss and Revenue Expectations:
During the July to September 2023 reporting cycle, Invivo Therapeutics Holdings Corp's operating loss stood at $-2.828 million. Although this figure doesn't align with the stockholders' expectations, they remain optimistic about the future revenue streams the company could acquire. While the current proficiency of the organization may not be a primary concern for shareholders, the reduction in losses to $-2.697 million (from $-2.755 million) during the third quarter of 2022 is seen as a positive sign.

Invivo Therapeutics Holdings Corp

Intriguing Progress: Invivo Therapeutics' Operating Loss Narrows to $-2.73 Million, Unveiling Promising Advances in the Medical Equipment & Supplies Sector

Over the past five days, Invivo Therapeutics Holdings Corp (NVIV) stock has experienced a decline of -1.49%, adding to its year-to-date performance which now stands at -42.36%. Currently trading on the NASDAQ, the stock is -45.2% below its 52 week averageAs earnings for the fiscal cycle of April to June 30, 2023 continue to be reported, many companies, including several in the Medical Equipment & Supplies sector, have disclosed their respective numbers. One such company is NVIV, which recently announced an operating loss of $-2.085 million for the second quarter of 2023. However, it is worth noting that the recent decisions regarding day-to-day operations have overshadowed those made in the second quarter of 2022.
An important aspect of NVIV's operations is that it primarily operates in the development stage. This is a significant observation in the current scenario. Additionally, there is some contentment regarding the net loss as it has been reduced compared to the same time frame in the previous year. This is a crucial observation for the fiscal period ending in the second quarter of 2023, where the deficit decreased from $-2.719 million in the second quarter of 2022 to $-1.937 million.
Investors and market participants are keenly awaiting the next financial results from NVIV, which are expected to be reported on November 6, 2023. This will provide further insight into the company's performance and potentially impact its stock performance going forward.

Invivo Therapeutics Holdings Corp

NVIV Exhibits Impressive Financial Recovery Amidst Global Economic Challenges

Invivo Therapeutics Holdings Corp, an emerging growth business, has shown significant improvement in efficiency and perseverance amidst a challenging global financial landscape. Despite the fact that shareholders didn't anticipate certain adjustments in the company's operations during the January to March 31 2023 reporting cycle, the company has displayed an impressive reduction from an operating shortfall of $-2.665 million to $-2.488 million.
This improved financial performance is a testament to the company's strategic management and operational efficiencies, which have allowed it to save large sums of money while still expanding revenue streams. This is evident in the $-2.332 million saved in the first quarter of 2023, compared to the $-2.655 million saved in the first quarter of 2022.
Looking ahead, Invivo Therapeutics Holdings Corp is expected to report next financial earnings on August 07, 2023, and given the company's recent financial performance, investors and shareholders are anticipating a positive report. Despite a cumulative net loss of $-10 million during the 12 months ending in the first quarter of 2023, the company's overall ranking has advanced, thus indicating a promising future for the company.
While the negative return on equity (ROE) of -78.01% may be seen as a concern for some investors, it's important to note that within the Medical Equipment & Supplies industry, 78 other companies had a higher return on equity. Additionally, the company has shown steady improvement in its ROE ranking, moving up from a total ranking of 3797 in the fourth quarter of 2022 to 2496 in the current quarter.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com